Key facts
- It has raised $1.7M; the latest was Grant ($1.3M) in Jan 2025.
- Notable investors include BioAdvance Capital (Conshohocken), H. Lundbeck, Michael J. Fox Foundation, The ALS Association.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ossianix
- ·The full record, as it builds
Funding rounds
No funding rounds for Ossianix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ossianix
Operator of a protein engineering company intended to develop biological therapeutics. The company offers products using single-domain antibodies from sharks and specializes in treating nervous system disorders, inflammation, and metabolic and muscular diseases, while developing blood-brain barrier antibody transporter for therapeutics including peptides, antibodies, and large enzymes, enabling healthcare providers to cure patients and improve their lives
- Sector
- Healthcare
- HQ
- Stevenage, United Kingdom
- Founded
- 2010
- Employees
- 8
- Website
- ossianix.co.uk/
- Ownership
- Privately Held (backing)
Ossianix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ossianix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ossianix in its N-PORT filings yet. We sweep new filings monthly.